CytomX Therapeutics, Inc. — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. This is an annual report, not a standalone Q4 filing; selected Q4 figures are noted below. CytomX is a clinical-stage oncology biopharmaceutical company developing masked antibody therapeutics through its Probody platform. It had no approved products or product-sale revenue.
Financial performance and position
| Metric | FY2016 | FY2015 |
|---|---|---|
| Total revenue | $15.0 million | $7.7 million |
| Research and development expense | $54.8 million | $28.4 million |
| General and administrative expense | $19.9 million | $12.6 million |
| Operating loss | $59.6 million | $33.2 million |
| Net loss | $58.9 million | $35.4 million |
| Net loss per share, basic and diluted | $1.63 | $4.90 |
| Operating cash flow | $(2.0) million | $(27.4) million |
| Cash, cash equivalents and short-term investments at year-end | $181.9 million | $186.7 million |
| Working capital at year-end | $152.4 million | $174.0 million |
| Total long-term debt | None | None |
Revenue consisted primarily of collaboration-related license payments and research reimbursements; the filing reports no product sales. Operating expenses substantially exceeded revenue, so operating and profit margins were negative. The 2016 operating cash outflow was much smaller than the net loss, primarily reflecting increased deferred revenue from partner payments. Investing activities provided $45.9 million, mainly from maturities of marketable securities; financing activities provided $1.0 million. The former debt facility was repaid and terminated in 2015.
For Q4 2016, revenue was $6.3 million, net loss was $14.0 million, and basic and diluted loss per share was $0.39.
Material changes versus prior year
- Revenue rose $7.3 million, largely from recognition of AbbVie upfront payments and BMS target-selection and milestone payments.
- R&D expense increased $26.4 million, driven by manufacturing and program costs, clinical development, personnel, stock compensation, and the move to a larger facility. G&A expense increased $7.3 million, including higher stock compensation and professional-service and personnel costs.
- Net loss widened by $23.5 million. Loss per share improved from $4.90 to $1.63, but the comparison is affected by the 2015 IPO, preferred-stock conversion and resulting increase in weighted-average shares.
- Year-end cash, cash equivalents and investments declined $4.8 million. Working capital fell $21.6 million, while total liabilities increased to $120.6 million, largely reflecting deferred collaboration revenue rather than debt.
Outlook, developments and risks
- CytomX received FDA clearance for the CX-072 IND in December 2016 and dosed the first patient in its Phase 1/2 trial in January 2017. The trial evaluates CX-072 alone and in combinations. Initial clinical data were expected to emerge in late 2017 and through 2018.
- Management expected to file an IND for CX-2009 in the first half of 2017 and begin a Phase 1 trial in 2017. CX-2029, partnered with AbbVie, was in IND-enabling studies.
- Management estimated that existing capital would fund operations into 2019 under its current operating plan. It expected substantial future losses and R&D spending, and stated that additional funding would be needed; timing and terms of future financing were uncertain.
- Key collaborations include AbbVie (CD71 co-development and up to two discovery targets), BMS (four selected targets), ImmunoGen (CX-2009 drug-conjugate technology), and Pfizer (work continuing on two targets after Pfizer’s fourth-target option lapsed). Milestones and royalties are contingent and not assured; partners generally control later-stage development or commercialization for partnered programs.
- The central business risk is clinical and platform validation: CX-072 was at the beginning of human testing, while most other candidates remained preclinical. The filing highlights uncertain safety and efficacy, trial delays or failure, manufacturing and third-party dependence, competition, intellectual-property challenges, and reliance on collaboration payments.
- Revenue and receivables were concentrated: one unnamed customer represented 64% of FY2016 revenue and 93% of year-end accounts receivable. No material litigation was reported. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor issued an unqualified opinion.
Important facts for investors to verify
- Progress, enrollment, safety findings and clinical data from the CX-072 trial, including its combination arms; verify subsequent CX-2009 IND and trial milestones.
- Cash runway assumptions, actual operating cash burn, and the timing and terms of any future financing.
- Revenue composition and concentration by collaboration partner, including the identity and payment status of the customer accounting for the largest revenue and receivable shares.
- Whether collaboration milestones, partner development plans and potential royalties materialize; review termination rights and CytomX’s cost-sharing exposure under AbbVie’s CD71 agreement.
- Deferred revenue recognition, the substantial lease commitment (approximately $46.4 million of disclosed future minimum payments), and any changes in liabilities or liquidity after year-end.